-Down to Earth Report by children's non-profit links childhood malnourishment to educational performance, adult income and GDP Malnutrition decrease the gross domestic product (GDP) in low- and middle-income countries, says a report by international non-profit Save the Children. Malnutrition affects educational development, physical productivity and health, and also perpetuates inequalities, such as those created by caste in India, says the report. The report, Food for thought: Tackling child malnutrition to unlock potential...

-The Times of India NEW DELHI: KartikSawhney had to wage a battle before being allowed to study science in class XI. The CBSE was not convinced Kartik, who is completely blind, would be able to handle the 'visual inputs' - graphs, diagrams, models - required for science. The doubters got their answer on Monday. Kartik scored a 95% aggregate in science with computers in class XII. The DPS, R K Puram, student...

-The Hindustan Times Although crusader-turned-politician Arvind Kejriwal seems optimistic about his Aam Aadmi Party's (AAP) performance in the upcoming Delhi assembly polls, many voters apparently think otherwise. Many of the voters in Delhi hail Kejriwal's decision of launching the party, but they are not sure whether they would exercise their franchise in favour of the newly-launched 'people's party'. According to them, the party lacks local presence, has a one-point agenda and indicates no...

-The Business Standard Patient safety & quality our guidance now, says Sawhney Trouble-hit Ranbaxy Laboratories has introduced a whistle-blower policy within the company to encourage transparency and address concerns internally, so that bigger problems could be averted. In his first interaction with the media (the first part of which was published on Sunday) since the drug maker pleaded guilty of making fraudulent statements to the US Food and Drugs Administration (FDA) under its...

-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...